Advances in radiotherapy based comprehensive treatment of primary hepatocellular carcinoma with portal vein tumor thrombus
Chen Lining1, Tang Yuan2, Jin Jing1,2
1Department of Radiation Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China; 2Department of Radiation Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract：Primary hepatocellular carcinoma is the fourth most common malignant tumor in China, with the 2nd highest mortality rate. Clinical prognosis of hepatocellular carcinoma complicated with portal vein tumor thrombus is extremely poor. At present, multiple interventions have been adopted to treat primary hepatocellular carcinoma complicated with portal vein tumor thrombus, such as surgery, radiotherapy and targeted therapy, etc. In this article, the treatment of primary hepatocellular carcinoma with portal vein tumor thrombus was summarized, and the effect and prospect of radiotherapy based comprehensive treatment were illustrated.
Chen Lining,Tang Yuan,Jin Jing. Advances in radiotherapy based comprehensive treatment of primary hepatocellular carcinoma with portal vein tumor thrombus[J]. Chinese Journal of Radiation Oncology, 2022, 31(10): 955-960.
[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. [2] 郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2019,41(1):19‐28.DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005. Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015 [J]. Chin J Oncol,2019,41(1):19‐28.DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005. [3] Titano J, Noor A, Kim E.Transarterial chemoembolization and radioembolization across barcelona clinic liver cancer stages[J]. Semin Intervent Radiol, 2017,34(2):109-115. DOI: 10.1055/s-0037-1602709. [4] Han K, Kim JH, Ko GY, et al.Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review[J]. World J Gastroenterol, 2016,22(1):407-416. DOI: 10.3748/wjg.v22.i1.407. [5] Yu SJ, Kim YJ.Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein[J]. World J Hepatol, 2015,7(11):1553-1561. DOI: 10.4254/wjh.v7.i11.1553. [6] Connolly GC, Chen R, Hyrien O, et al.Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma[J]. Thromb Res, 2008,122(3):299-306. DOI: 10.1016/j.thromres.2007.10.009. [7] Llovet JM, Bustamante J, Castells A, et al.Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[J]. Hepatology, 1999,29(1):62-67. DOI: 10.1002/hep.510290145. [8] Minagawa M, Makuuchi M.Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus[J]. World J Gastroenterol, 2006,12(47):7561-7567. DOI: 10.3748/wjg.v12.i47.7561. [9] Schöniger-Hekele M, Müller C, Kutilek M, et al.Hepatocellular carcinoma in Central Europe: prognostic features and survival[J]. Gut, 2001,48(1):103-109. DOI: 10.1136/gut.48.1.103. [10] Kudo M, Izumi N, Kubo S, et al.Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan[J]. Hepatol Res, 2020,50(1):15-46. DOI: 10.1111/hepr.13438. [11] Cheng SQ, Wu MC, Chen H, et al.Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein[J]. Hepatogastroenterology, 2007,54(74):499-502. [12] Shi J, Lai EC, Li N, et al.A new classification for hepatocellular carcinoma with portal vein tumor thrombus[J]. J Hepatobiliary Pancreat Sci, 2011,18(1):74-80. DOI: 10.1007/s00534-010-0314-0. [13] Shui Y, Yu W, Ren X, et al.Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis[J]. Radiat Oncol, 2018,13(1):188. DOI: 10.1186/s13014-018-1136-5. [14] Xu JF, Liu XY, Wang S, et al.Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus: a novel classification[J]. World J Surg Oncol, 2015,13:86. DOI: 10.1186/s12957-015-0493-x. [15] Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer[M]. 2nd ed. [S.l.]: TokyoKanehara Co., Ltd, 1987. [16] Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer[M]. 2nd English ed. [S.l.]: TokyoKanehara Co., Ltd, 2003. [17] Katagiri S, Yamamoto M.Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus[J]. Surg Today, 2014,44(2):219-226. DOI: 10.1007/s00595-013-0585-6. [18] Yu JI, Park HC.Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis[J]. World J Gastroenterol, 2016,22(30):6851-6863. DOI: 10.3748/wjg.v22.i30.6851. [19] Kang JB, Nie Q, Du R, et al.Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Mol Clin Oncol, 2014,2(1):43-50. DOI: 10.3892/mco.2013.196. [20] Im JH, Yoon SM, Park HC, et al.Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area[J]. Liver Int, 2017,37(1):90-100. DOI: 10.1111/liv.13191. [21] Wei X, Jiang Y, Zhang X, et al.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study[J]. J Clin Oncol, 2019,37(24):2141-2151. DOI: 10.1200/JCO.18.02184. [22] Bai T, Chen J, Xie ZB, et al.The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus[J]. Onco Targets Ther, 2016,9:3841-3848. DOI: 10.2147/OTT.S104307. [23] Sun J, Yang L, Shi J, et al.Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial[J]. Radiother Oncol, 2019,140:20-25. DOI: 10.1016/j.radonc.2019.05.006. [24] Choi JY, Yu JI, Park HC, et al.The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus[J]. Liver Transpl, 2017,23(4):545-551. DOI: 10.1002/lt.24729. [25] Yoon SM, Lim YS, Won HJ, et al.Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2012,82(5):2004-2011. DOI: 10.1016/j.ijrobp.2011.03.019. [26] Lu DH, Fei ZL, Zhou JP, et al.A comparison between three-dimensional conformal radiotherapy combined with interventional treatment and interventional treatment alone for hepatocellular carcinoma with portal vein tumour thrombosis[J]. J Med Imaging Radiat Oncol, 2015,59(1):109-114. DOI: 10.1111/1754-9485.12207. [27] Li XL, Guo WX, Hong XD, et al.Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis[J]. Hepatol Res, 2016,46(11):1088-1098. DOI: 10.1111/hepr.12657. [28] Li X, Guo W, Guo L, et al.Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study[J]. Oncotarget, 2018,9(36):24537-24547. DOI: 10.18632/oncotarget.25224. [29] Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol, 2018,4(5):661‐669.DOI: 10.1001/jamaoncol. 2017.5847. [30] Zeng ZC, Fan J, Tang ZY, et al.A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus[J]. Int J Radiat Oncol Biol Phys, 2005,61(2):432-443. DOI: 10.1016/j.ijrobp.2004.05.025. [31] Tazawa J, Maeda M, Sakai Y, et al.Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement[J]. J Gastroenterol Hepatol, 2001,16(6):660-665. DOI: 10.1046/j.1440-1746.2001.02496.x. [32] Hsu HC, Chen TY, Chiu KW, et al.Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma[J]. Br J Radiol, 2007,80(949):38-42. DOI: 10.1259/bjr/55395102. [33] Llovet JM, Ricci S, Mazzaferro V, et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008,359(4):378-390. DOI: 10.1056/NEJMoa0708857. [34] Cheng AL, Kang YK, Chen Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009,10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. [35] Jeong SW, Jang JY, Shim KY, et al.Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis[J]. Gut Liver, 2013,7(6):696-703. DOI: 10.5009/gnl.2013.7.6.696. [36] Kudo M, Finn RS, Qin S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018,391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. [37] Gordan JD, Kennedy EB, Abou-Alfa GK, et al.Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline[J]. J Clin Oncol, 2020,38(36):4317-4345. DOI: 10.1200/JCO.20.02672. [38] Que J, Wu HC, Lin CH, et al.Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Medicine (Baltimore), 2020,99(13):e19660. DOI: 10.1097/MD.0000000000019660. [39] Kim BK, Kim DY, Byun HK, et al.Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma: a prospective phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2020,107(1):106-115. DOI: 10.1016/j.ijrobp.2020.01.027. [40] Granier C, De Guillebon E, Blanc C, et al.Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer[J]. ESMO Open, 2017,2(2):e000213. DOI: 10.1136/esmoopen-2017-000213.
2022, Vol. 31 
